Peter Margolis, MD
Internal Medicine · Thousand Oaks, CANPI 1306876164
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,923 of the $59,004 with a category attached, or 99.9%. Ultragenyx Pharmaceutical Inc. accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $58,923 and has fallen 100.0% since, to $27 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $907.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$59K
- Astellas Pharma US Inc$55
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27
What the payments were for
- Consulting fees$58,923100%
- Food & beverage$270%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 63 | $58,923 |
| Astellas Pharma US Inc | 1 | $55 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $27 |
How this compares
$59,004 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $65,698 |
| XareltoRivaroxaban | 28 | $29,867 |
| JanuviaSitagliptin Phosphate | 18 | $27,492 |
| JardianceEmpagliflozin | 18 | $18,731 |
| FarxigaDapagliflozin Propanediol | 22 | $16,645 |
| MultaqDronedarone Hcl | 11 | $8,095 |
| TradjentaLinagliptin | 12 | $6,191 |
| Rosuvastatin Calcium | 147 | $2,614 |
| Atorvastatin Calcium | 244 | $2,326 |
| Famotidine | 147 | $2,153 |
| Levothyroxine Sodium | 122 | $1,408 |
| Ezetimibe | 46 | $1,242 |
| Escitalopram Oxalate | 69 | $1,093 |
| Memantine Hcl | 28 | $1,044 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 27 | $1,011 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Thousand Oaks
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.